The PE Ratio as of December 2024 (TTM) for MoonLake Immunotherapeutics (MLTX) is -41.62

According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current PE Ratio is -41.62. This represents a change of -26.58% compared to the average of -56.69 of the last 4 quarters.

MoonLake Immunotherapeutics (MLTX) Historical PE Ratio (quarterly & annually)

How has MLTX PE Ratio performed in the past?

The mean historical PE Ratio of MoonLake Immunotherapeutics over the last ten years is -485.43. The current -41.62 PE Ratio has changed 757.38% with respect to the historical average. Over the past ten years (40 quarters), MLTX's PE Ratio was at its highest in in the June 2022 quarter at -2.65. The PE Ratio was at its lowest in in the March 2021 quarter at -494.85.

MoonLake Immunotherapeutics (MLTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of MoonLake Immunotherapeutics PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MoonLake Immunotherapeutics (MLTX) Average PE Ratio

How has MLTX PE Ratio performed in the past?

The current PE Ratio of MoonLake Immunotherapeutics (MLTX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

MoonLake Immunotherapeutics (MLTX) PE Ratio vs. Peers

How is MLTX’s PE Ratio compared to its peers?

MoonLake Immunotherapeutics’s PE Ratio is less than Terns Pharmaceuticals, Inc. (0), less than Day One Biopharmaceuticals, Inc. (-5.13), less than Acumen Pharmaceuticals, Inc. (-14.42), less than Amylyx Pharmaceuticals, Inc. (-1.32), less than Aerovate Therapeutics, Inc. (-1.06), less than Enliven Therapeutics, Inc. (-0.88), less than Structure Therapeutics Inc. (-13.11), less than Compass Therapeutics, Inc. (-12.68), less than Ventyx Biosciences, Inc. (-4.34), less than Nuvalent, Inc. (-1.06), less than Cerevel Therapeutics Holdings, Inc. (-24.25), less than Travere Therapeutics, Inc. (-17.73), less than Arcellx, Inc. (-3.80), greater than Akero Therapeutics, Inc. (-102.80), less than 89bio, Inc. (-8.37), less than Pliant Therapeutics, Inc. (-2.96), less than null (-4.04),

Build a custom stock screener for MoonLake Immunotherapeutics (MLTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MoonLake Immunotherapeutics (MLTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.